Smith+Nephew Publishes New Wound Therapy Guidelines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- New Guidelines Released: Smith+Nephew has published new consensus guidelines for single-use negative pressure wound therapy (sNPWT), developed by expert clinicians in Germany, aimed at improving treatment outcomes for closed surgical incisions, reinforcing the company's leadership in wound management.
- Economic Impact Analysis: The new guidelines indicate that prophylactic negative pressure wound therapy can not only enhance clinical outcomes but also significantly reduce healthcare costs, for instance, the length of stay for patients with wound healing complications can be halved to 9 days compared to standard treatment, highlighting its economic importance.
- Clinical Application Recommendations: The guidelines recommend the use of sNPWT in high-risk patients based on a risk score for transparent clinical decision-making, aiming to reduce postoperative complications and infections, thereby optimizing the use of healthcare resources and enhancing hospital operational efficiency.
- Advantages of PICO 7 Device: The PICO 7 device is designed to be portable and single-use, capable of being used in both inpatient and outpatient settings, delivering negative pressure of up to -80 mmHg, and its various features facilitate seamless integration into existing care pathways, further enhancing patient treatment experiences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNN
Wall Street analysts forecast SNN stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 30.480
Low
34.00
Averages
35.75
High
37.50
Current: 30.480
Low
34.00
Averages
35.75
High
37.50
About SNN
Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Smith+Nephew Publishes New Wound Therapy Guidelines
- New Guidelines Released: Smith+Nephew has published new consensus guidelines for single-use negative pressure wound therapy (sNPWT), developed by expert clinicians in Germany, aimed at improving treatment outcomes for closed surgical incisions, reinforcing the company's leadership in wound management.
- Economic Impact Analysis: The new guidelines indicate that prophylactic negative pressure wound therapy can not only enhance clinical outcomes but also significantly reduce healthcare costs, for instance, the length of stay for patients with wound healing complications can be halved to 9 days compared to standard treatment, highlighting its economic importance.
- Clinical Application Recommendations: The guidelines recommend the use of sNPWT in high-risk patients based on a risk score for transparent clinical decision-making, aiming to reduce postoperative complications and infections, thereby optimizing the use of healthcare resources and enhancing hospital operational efficiency.
- Advantages of PICO 7 Device: The PICO 7 device is designed to be portable and single-use, capable of being used in both inpatient and outpatient settings, delivering negative pressure of up to -80 mmHg, and its various features facilitate seamless integration into existing care pathways, further enhancing patient treatment experiences.
See More
Smith+Nephew Releases New Consensus Guidance on sNPWT
- New Consensus Guidance Released: Smith+Nephew has published Germany's first consensus guidance on single-use negative pressure wound therapy (sNPWT) in the internationally recognized journal Die Chirurgie, aiming to provide a practical framework for post-surgical care that reduces the risk of complications and enhances treatment outcome predictability.
- Recommendations for At-Risk Patients: The consensus identifies sNPWT as suitable for patients at increased risk of postoperative complications, such as those with obesity, diabetes, and smoking habits, enabling healthcare professionals to tailor interventions based on individual risk profiles and optimize clinical decision-making.
- Advantages of PICO 7 Device: The PICO 7 device is designed for ease of use in both inpatient and outpatient settings, featuring a canister-free system and lightweight pump unit, along with visual indicators and various dressing configurations that facilitate integration into established clinical pathways and support continuity of therapy.
- Significant Clinical Benefits: The clinically relevant effects of controlled negative pressure therapy have been demonstrated, with PICO 7's proprietary AIRLOCK technology promoting healing by locking away over 99% of bacteria and allowing approximately 80% of exudate to evaporate, thus creating an optimal healing environment for wounds.
See More
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
Smith+Nephew Completes First Clinical Cases with CORI XT Surgical Platform
- Surgical Platform Innovation: Smith+Nephew's CORI XT handheld robotic platform successfully completed its first shoulder arthroplasty at Duke Health, marking the platform's debut in shoulder surgeries and showcasing its potential and technological advantages in surgical applications.
- Versatile Applications: The CORI XT platform not only excelled in shoulder arthroplasty but also completed its first knee replacement at NYU Langone Health, further proving its adaptability and flexibility across different surgical environments.
- Enhanced Surgical Efficiency: Designed to improve surgical precision while maintaining workflow efficiency, the platform allows surgeons to operate without altering existing procedures, thereby enhancing operational flow and patient recovery potential.
- Strategic Market Expansion: Through the clinical application of the CORI XT platform, Smith+Nephew demonstrates its innovative capabilities in medical technology, which is expected to drive further growth in the global orthopedic market and strengthen its competitive position.
See More
Smith+Nephew Launches Next-Gen LEAF Patient Monitoring System in the US
- Market Demand Response: Smith+Nephew's LEAF Patient Monitoring System addresses the approximately 60,000 annual deaths in the US attributed to hospital-acquired pressure injuries (HAPIs), potentially significantly reducing the economic burden of up to $26.8 billion annually on healthcare systems.
- Technological Innovation: The system utilizes a wearable sensor to monitor patient mobility in real-time, enhancing workflow efficiency and protocol adherence, thereby ensuring timely care for patients amidst staffing shortages and workload pressures.
- User Experience Optimization: The cloud-hosted LEAF system, designed in consultation with multidisciplinary nursing teams, features an intuitive user interface and document automation, enabling nurses to quickly access critical information and streamline patient management processes.
- Significant Economic Benefits: The LEAF system monitors over 150,000 patients annually in a critical care facility, reducing the odds of HAPIs by up to 73% and delivering estimated savings of up to $1.8 million, highlighting its critical value in the healthcare industry.
See More
Surge of Regenerative Medicine IPOs
- New Company Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with over 25.2 million shares issued, as CEO emphasized their CXU™ platform's goal to rebuild biological structures, potentially attracting significant investor interest in regenerative medicine.
- Significant Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025, with gross margins at a historic high of 79.4%, reflecting strong demand for its non-opioid pain therapies, which may lead to increased capital inflows into related companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and equivalents with no debt in Q1 2026, and its TrueDent® resins received CE marking, enhancing its penetration in the European market and strengthening the bioprinting industry's infrastructure.
- Wound Care Innovation: Smith & Nephew launched ALLEVYN COMPLETE CARE Foam Dressing in the U.S. in March 2026, targeting chronic wound management with robust scientific backing, addressing the growing global demand for wound care and further expanding the regenerative medicine market.
See More
Smith+Nephew Publishes New Wound Therapy Guidelines
- New Guidelines Released: Smith+Nephew has published new consensus guidelines for single-use negative pressure wound therapy (sNPWT), developed by expert clinicians in Germany, aimed at improving treatment outcomes for closed surgical incisions, reinforcing the company's leadership in wound management.
- Economic Impact Analysis: The new guidelines indicate that prophylactic negative pressure wound therapy can not only enhance clinical outcomes but also significantly reduce healthcare costs, for instance, the length of stay for patients with wound healing complications can be halved to 9 days compared to standard treatment, highlighting its economic importance.
- Clinical Application Recommendations: The guidelines recommend the use of sNPWT in high-risk patients based on a risk score for transparent clinical decision-making, aiming to reduce postoperative complications and infections, thereby optimizing the use of healthcare resources and enhancing hospital operational efficiency.
- Advantages of PICO 7 Device: The PICO 7 device is designed to be portable and single-use, capable of being used in both inpatient and outpatient settings, delivering negative pressure of up to -80 mmHg, and its various features facilitate seamless integration into existing care pathways, further enhancing patient treatment experiences.
See More
Smith+Nephew Releases New Consensus Guidance on sNPWT
- New Consensus Guidance Released: Smith+Nephew has published Germany's first consensus guidance on single-use negative pressure wound therapy (sNPWT) in the internationally recognized journal Die Chirurgie, aiming to provide a practical framework for post-surgical care that reduces the risk of complications and enhances treatment outcome predictability.
- Recommendations for At-Risk Patients: The consensus identifies sNPWT as suitable for patients at increased risk of postoperative complications, such as those with obesity, diabetes, and smoking habits, enabling healthcare professionals to tailor interventions based on individual risk profiles and optimize clinical decision-making.
- Advantages of PICO 7 Device: The PICO 7 device is designed for ease of use in both inpatient and outpatient settings, featuring a canister-free system and lightweight pump unit, along with visual indicators and various dressing configurations that facilitate integration into established clinical pathways and support continuity of therapy.
- Significant Clinical Benefits: The clinically relevant effects of controlled negative pressure therapy have been demonstrated, with PICO 7's proprietary AIRLOCK technology promoting healing by locking away over 99% of bacteria and allowing approximately 80% of exudate to evaporate, thus creating an optimal healing environment for wounds.
See More
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
Smith+Nephew Completes First Clinical Cases with CORI XT Surgical Platform
- Surgical Platform Innovation: Smith+Nephew's CORI XT handheld robotic platform successfully completed its first shoulder arthroplasty at Duke Health, marking the platform's debut in shoulder surgeries and showcasing its potential and technological advantages in surgical applications.
- Versatile Applications: The CORI XT platform not only excelled in shoulder arthroplasty but also completed its first knee replacement at NYU Langone Health, further proving its adaptability and flexibility across different surgical environments.
- Enhanced Surgical Efficiency: Designed to improve surgical precision while maintaining workflow efficiency, the platform allows surgeons to operate without altering existing procedures, thereby enhancing operational flow and patient recovery potential.
- Strategic Market Expansion: Through the clinical application of the CORI XT platform, Smith+Nephew demonstrates its innovative capabilities in medical technology, which is expected to drive further growth in the global orthopedic market and strengthen its competitive position.
See More
Smith+Nephew Launches Next-Gen LEAF Patient Monitoring System in the US
- Market Demand Response: Smith+Nephew's LEAF Patient Monitoring System addresses the approximately 60,000 annual deaths in the US attributed to hospital-acquired pressure injuries (HAPIs), potentially significantly reducing the economic burden of up to $26.8 billion annually on healthcare systems.
- Technological Innovation: The system utilizes a wearable sensor to monitor patient mobility in real-time, enhancing workflow efficiency and protocol adherence, thereby ensuring timely care for patients amidst staffing shortages and workload pressures.
- User Experience Optimization: The cloud-hosted LEAF system, designed in consultation with multidisciplinary nursing teams, features an intuitive user interface and document automation, enabling nurses to quickly access critical information and streamline patient management processes.
- Significant Economic Benefits: The LEAF system monitors over 150,000 patients annually in a critical care facility, reducing the odds of HAPIs by up to 73% and delivering estimated savings of up to $1.8 million, highlighting its critical value in the healthcare industry.
See More
Surge of Regenerative Medicine IPOs
- New Company Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with over 25.2 million shares issued, as CEO emphasized their CXU™ platform's goal to rebuild biological structures, potentially attracting significant investor interest in regenerative medicine.
- Significant Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025, with gross margins at a historic high of 79.4%, reflecting strong demand for its non-opioid pain therapies, which may lead to increased capital inflows into related companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and equivalents with no debt in Q1 2026, and its TrueDent® resins received CE marking, enhancing its penetration in the European market and strengthening the bioprinting industry's infrastructure.
- Wound Care Innovation: Smith & Nephew launched ALLEVYN COMPLETE CARE Foam Dressing in the U.S. in March 2026, targeting chronic wound management with robust scientific backing, addressing the growing global demand for wound care and further expanding the regenerative medicine market.
See More
